Multimodality Approaches for Pancreatic Cancer
نویسندگان
چکیده
منابع مشابه
Multimodality approaches for the curative treatment of esophageal cancer.
Carcinoma of the esophagus and gastroesophageal junction tumors presenting with locoregional disease are potentially curable, although the cure rate is modest. Many different treatment approaches have been studied, with a multimodality approach associated with a 10% to 15% greater survival advantage compared with a single-modality approach. A systematic review was conducted to address 3 clinica...
متن کاملTreatment approaches for interstitial cystitis: multimodality therapy.
Interstitial cystitis is an increasingly common disease characterized by urgency, frequency, and pelvic pain. Its etiology is poorly understood but is likely to be multifactorial. A proposed pathophysiology describing a cascade of events, including epithelial dysfunction, mast cell activation, and neurogenic inflammation, is presented. Using this model, multimodality therapy regimens have been ...
متن کاملThoracoscopic Splanchnicectomy for Pain Control in Irresectable Pancreatic Cancer
Introduction : Severepain is a major problem in patients with unresectable pancreatic cancer. The goal of this study is to evaluate the effects of Thoracoscopic Splanchnicectomy (TS) on pain control in these patients suffering from unresectable pancreatic cancer. Methods:Between years 2000 to 2011, 20 patients suffering from unresectable pancreatic cancer underwent TS due to severe pain. They w...
متن کاملCurrent Immunotherapeutic Approaches in Pancreatic Cancer
Pancreatic cancer is a highly aggressive and notoriously difficult to treat. As the vast majority of patients are diagnosed at advanced stage of the disease, only a small population is curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. Thus, new therapeutic approaches are needed. Pa...
متن کاملNew approaches tackle rising pancreatic cancer rates.
Taking the immunomodulator simtuzumab with gemcitabine did not statistically significantly increase progression-free survival in advanced pancreatic cancer, according to a phase II study. Simtuzumab’s maker, Gilead Sciences (Foster City, Calif.), reported results of the double-blind randomized trial of 236 patients in September. Stromal targeting is one of several new approaches to treating thi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CA: A Cancer Journal for Clinicians
سال: 2005
ISSN: 0007-9235
DOI: 10.3322/canjclin.55.6.352